The Biosimilars Council released a new analysis by IQVIA that reveals a PBM strategy to protect $2 billion in profits by “strangling” the biosimilar market and preventing savings for patients.
Following the transaction, Grown Alchemist will focus on large-scale partnerships and activations in lifestyle, music and retail to help drive international growth in key markets.
Migalastat Capsules are indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
